Psychoactives
September 11, 2025
Tereza Dleštíková
4 citations
Czechia has recently approved the medical use of psilocybin, marking a pivotal shift in the country’s drug policy landscape. This development paves the way for regulated therapeutic applications of psilocybin within clinical settings, while simultaneously prompting a timely discussion on the potential uses of psychedelics beyond strictly medical contexts. This commentary first outlines the...
ACS Pharmacology & Translational Science
September 11, 2025
Noelle Cataldo, John A. Razidlo, Cody J. Wenthur
2 citations
Serotonergic psychedelics have shown promise in clinical trials for treating an array of mental health disorders, including depression, anxiety, and post-traumatic stress disorder. Despite these findings, our understanding of how these drugs mechanistically exert their therapeutic effects remains incomplete. While researchers have regularly employed rodent preclinical models to assess such...
University of Southern Denmark Research Portal (University of Southern Denmark)
September 9, 2025
Jacob Cohen
Angst og traumarelaterede lidelser,herunder generaliseret angstlidelse (GAD), obsessiv-kompulsiv lidelse (OCD), posttraumatisk stresslidelse (PTSD) og social angstlidelse (SAD), er meget udbredte og reagerer ofte dårligt på konventionel farmakologisk behandling og psykoterapi. Nyere kliniske forsøg har vist, at psykedeliske stoffer og ketamin kan udøve hurtige og vedvarende effekter gennem...
Journal of Psychedelic Studies
September 4, 2025
Alan K. Davis, Meghan DellaCrosse, Nathan D. Sepeda et al.
4 citations
Abstract Background Major Depressive Disorder (MDD) is a leading cause of disability and economic loss, with high recurrence and treatment resistance. Psilocybin-assisted therapy (PAT) shows promise in reducing depressive symptoms, but long-term effects are unknown. We aimed to determine the long-term safety and efficacy of PAT for MDD over a five-year follow-up period. Methods Individuals who...
Acta Neuropsychiatrica
September 3, 2025
Filipe Reis Teodoro Andrade, Tobias Buchborn, Gabriel Thalheimer et al.
3 citations
Abstract Background: Major depressive disorder (MDD) is a significant public health concern, and current treatments often have limitations in effectiveness and adherence. Psilocybin, a psychedelic compound found in certain mushrooms, is being explored as a potential treatment for depression. It primarily acts through the serotonin 5-HT2A receptor but interacts with 5-HT1A and 5-HT2C receptors....
Psychoactives
September 1, 2025
M Mercier, Cédric Mabilais, Vasileios Chytas et al.
Psychedelic substances have experienced a resurgence of clinical interest in recent years, particularly for their promising effects in the treatment of psychiatric disorders such as depression and anxiety. While evidence regarding their role in chronic pain management remains limited, emerging studies suggest potential therapeutic benefits. This case report describes a patient with persistent...
Clinical Neuropharmacology
September 1, 2025
Jaime Moreno‐chaparro, Gabriela Castañeda-millán, Javier Eslava‐schmalbach
3 citations
Objective: Due to the boom in the use of certain psychedelics in different neuropsychiatric conditions, the objective was to synthesize the available information on the use of psilocybin (a psychedelic) in the population with autism spectrum disorder (ASD; a developmental neuropsychiatric condition). Methods: Scoping review. Question framework: Population: people with ASD—Concept:...
International Journal of Innovative Technologies in Social Science
September 1, 2025
Anna Blazhkova, Magdalena Czaja, Hanna Sitka et al.
Introduction: Recently, there has been a significant increase in interest in the use of psychedelics for various psychiatric conditions. Psilocybin is receiving particular attention as a psychoactive substance with significant therapeutic potential. Recent research focuses on its possible benefits in the treatment of major depressive disorders (MDD) and anorexia nervosa (AN). Purpose of the...
Therapeutic Advances in Psychopharmacology
September 1, 2025
Stanley Wong, Gray Meckling, Nicholas Fabiano et al.
6 citations
Background: Suicidal ideation, attempts, and deaths present a major and tragic public health concern. Recent trials of psilocybin therapy (PT) have shown promise in treating treatment-resistant depression and have found a reduction in suicidal ideation. Given the growth of PT research, there is a need to further understand its effect on suicidal ideation, attempts, and deaths. Objective: To...
Therapeutic Advances in Psychopharmacology
September 1, 2025
Sally Meikle, Olivia Carter, Paul Liknaitzky et al.
2 citations
Background: Depressive disorders are a major global health challenge, with many individuals unresponsive to existing treatments. Novel psychedelic therapies show promise but require further research. Objectives: This study aimed to evaluate the feasibility, safety and effectiveness of psilocybin with psychotherapeutic support for treatment-resistant depression (TRD), investigate predictors of...